Please provide information on the profile and incidence of adverse reactions to terfenadine in comparison with other non sedative anti-histamines on the EU market used to alleviate the same pathological conditions, with particular reference to serious adverse events (with respect to cardiotoxicity and other effects), outcome and risk factors.